S2P Aperçu des actions Simcere Pharmaceutical Group Limited se consacre à la recherche, au développement, à la fabrication et à la vente de produits pharmaceutiques pour les distributeurs, les chaînes de pharmacies et d'autres fabricants de produits pharmaceutiques en Chine. Plus de détails
Récompenses Analyse des risques Voir tous les contrôles de risques Saisissez vos pensées, vos liens et l'histoire de votre entreprise
Simcere Pharmaceutical Group Limited Concurrents Historique des prix et performances
Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Simcere Pharmaceutical Group Historique des cours de bourse Prix actuel de l'action HK$0.81 Plus haut sur 52 semaines HK$0.89 Plus bas sur 52 semaines HK$0.57 Bêta 0.44 Variation sur 1 mois 0% Variation sur 3 mois 10.20% Variation sur 1 an 5.19% Variation sur 3 ans -16.92% Variation sur 5 ans n/a Évolution depuis l'introduction en bourse -44.14%
Nouvelles et mises à jour récentes
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29
Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration Sep 05
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Aug 25 Voir plus de mises à jour
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29
Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration Sep 05
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Aug 25
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
Now 22% overvalued Aug 03
Simcere Pharmaceutical Group Limited Announces New Drug Application of Quviviq (Daridorexant Hydrochloride Tablets) Has Been Accepted by the National Medical Products Administration Jul 17
Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug Jul 11
Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China Jun 25 Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024. Jun 20
Upcoming dividend of CN¥0.16 per share Jun 11
Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China Jun 01
Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong May 23
Full year 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.36 in FY 2022) Apr 26
Dividend of CN¥0.16 announced Mar 22 Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China Mar 16
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration Mar 13
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500 Mar 12
Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023 Feb 20
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19 Jan 19
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets Jan 12
Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Dec 27
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration Dec 04
Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration Nov 30
Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Oct 31
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration Oct 17
First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022) Sep 25
First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022) Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023 Aug 10
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 28
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 23
Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jul 01 Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jun 30
Co-Founder recently sold €271k worth of stock Jun 21
Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023 Jun 16
Upcoming dividend of CN¥0.16 per share at 2.3% yield Jun 12
Co-Founder recently sold €360k worth of stock May 01
Full year 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.58 in FY 2021) Apr 19
Investor sentiment improves as stock rises 19% Apr 13
Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration Jan 30
Investor sentiment deteriorated over the past week Jan 20
Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director Jan 19
Now 30% undervalued Jan 18
Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration Jan 17
Co-Founder recently bought €957k worth of stock Jan 11 Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023
Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration Dec 30
Investor sentiment improved over the past week Dec 30
Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment Dec 21
Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment Dec 19
Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study Dec 03
Insufficient new directors Nov 16
Simcere Pharmaceutical Group Limited Announces Executive Changes Nov 10
Investor sentiment improved over the past week Nov 03
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug Application Oct 28
Investor sentiment improved over the past week Oct 15
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 07
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 06
First half 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1H 2021) Sep 01
Simcere Pharmaceutical Group Limited Announces Executive and Committee Changes Sep 01
Simcere Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 31, 2022 Aug 20
Simcere Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022 Aug 02
Cosela, the World's First Comprehensive Myeloprotection Drug Against Chemotherapy Damage, Wins Approval in China Jul 19
Simcere Pharmaceutical Group Limited Announces Conditional Marketing of COSELA (Trilaciclib Hydrochloride for Injection) in China by the National Medical Products Administration Jul 14
Investor sentiment improved over the past week Jul 09
Simcere Pharmaceutical Group Limited Declares Final Dividend for the Year Ended December 31, 2021, Payable on July 15, 2022 Jun 25
Upcoming dividend of CN¥0.15 per share Jun 21 Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2021 Jun 02
Simcere Pharmaceutical Group Limited Announces Appointment of Tang Renhong as Co-Chief Executive Officer May 26
Investor sentiment improved over the past week May 18
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0417 (3Cl) Issued by the National Medical Products Administration May 17
CFO & Executive Director recently bought €66k worth of stock Apr 30
Full year 2021 earnings released: EPS: CN¥0.58 (vs CN¥0.28 in FY 2020) Apr 28
Less than half of directors are independent Apr 27
Simcere Pharmaceutical Group Limited Obtains Permission from the National Medical Products Administration of China to Conduct Clinical Trials Apr 01
Investor sentiment improved over the past week Mar 21
Vivoryon Therapeutics N.V. and Simcere Pharmaceutical Group Ltd Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease Mar 01
Simcere Pharmaceutical Group Announces Primary Endpoint Met in Phase III Clinical Trial of Trilaciclib in Chinese Patients with Small Cell Lung Cancer Feb 24
Simcere Pharmaceutical Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021 Feb 22
Simcere Pharmaceuticals Announces Appointment of Bijoyesh Mookerjee as Chief Medical Officer, Oncology Feb 08
Simcere Pharmaceutical Group Limited Announces the Approval of Investigational New Drug for SIM0235 Issued by U.S. Food and Drug Administration Jan 31
Investor sentiment improved over the past week Jan 18
Center for Drug Evaluation of the National Medical Products Administration of China Includes Simcere Pharmaceutical Group Limited's Trilaciclib Injection as a Priority Review Drug Dec 23 Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0235 Issued by National Medical Products Administration
Simcere Pharmaceutical Group Limited Announces Conditional Approval on the Marketing of Enweida (Envafolimab) in China by The national Medical Products Administration Nov 27
Investor sentiment improved over the past week Nov 19
Co-Founder recently bought €127k worth of stock Nov 02 Rendement pour les actionnaires S2P DE Pharmaceuticals DE Marché 7D -2.4% -0.3% -0.3% 1Y 5.2% -17.0% 7.0%
Voir le rapport complet des actionnaires
Rendement vs Industrie: S2P a dépassé le secteur German Pharmaceuticals qui a rapporté -17 % au cours de l'année écoulée.
Rendement vs marché: S2P a sous-performé le marché German qui a rapporté 7 % au cours de l'année écoulée.
Volatilité des prix Is S2P's price volatile compared to industry and market? S2P volatility S2P Average Weekly Movement 7.0% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Cours de l'action stable: S2P n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.
Volatilité au fil du temps: La volatilité hebdomadaire de S2P ( 7% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise Simcere Pharmaceutical Group Limited se consacre à la recherche, au développement, à la fabrication et à la vente de produits pharmaceutiques pour les distributeurs, les chaînes de pharmacies et d'autres fabricants de produits pharmaceutiques en Chine. L'entreprise se concentre sur divers domaines thérapeutiques, notamment l'oncologie, le système nerveux central, les maladies auto-immunes, les maladies infectieuses et les maladies cardiovasculaires. Ses principaux produits sont Sanbexin, une solution concentrée d'edaravone et de dexborneol pour injection ; Endostar, une injection d'endostatine humaine recombinante ; ENWEIDA, une injection d'envafolimab ; COSELA, un chlorhydrate de trilaciclib pour injection ; Iremod, un comprimé d'iguratimod ; et XIANNUOXIN, un comprimé de simnotrelvir/ritonavir.
Afficher plus Simcere Pharmaceutical Group Limited Résumé des fondamentaux Comment les bénéfices et les revenus de Simcere Pharmaceutical Group se comparent-ils à sa capitalisation boursière ? S2P statistiques fondamentales Capitalisation boursière €2.09b Bénéfices(TTM) -€145.12m Recettes(TTM ) €834.62m
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) S2P compte de résultat (TTM ) Recettes CN¥6.34b Coût des recettes CN¥1.45b Marge brute CN¥4.88b Autres dépenses CN¥5.99b Les revenus -CN¥1.10b
Derniers bénéfices déclarés
Jun 30, 2024
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) -0.44 Marge brute 77.05% Marge bénéficiaire nette -17.39% Ratio dettes/capitaux propres 14.5%
Quelles ont été les performances à long terme de S2P?
Voir les performances historiques et les comparaisons Dividendes
2.5% Rendement actuel des dividendes
-37% Ratio de distribution
Analyse de l'entreprise et données financières Données Dernière mise à jour (heure UTC) Analyse de l'entreprise 2024/12/26 00:24 Cours de l'action en fin de journée 2024/12/23 00:00 Les revenus 2024/06/30 Revenus annuels 2023/12/31
Sources de données Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC . Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
Paquet Données Cadre temporel Exemple de source américaine * Finances de l'entreprise 10 ans Compte de résultat Tableau des flux de trésorerie Bilan Estimations consensuelles des analystes +3 ans Prévisions financières Objectifs de prix des analystes Prix du marché 30 ans Cours des actions Dividendes, scissions et actions Propriété 10 ans Actionnaires principaux Délits d'initiés Gestion 10 ans L'équipe dirigeante Conseil d'administration Principaux développements 10 ans
* exemple pour les titres américains, pour les titres non-américains des formulaires et sources réglementaires équivalents sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). Pour en savoir plus , cliquez ici .
Modèle d'analyse et flocon de neige Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github . Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube .
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur .
Sources des analystes Simcere Pharmaceutical Group Limited est couverte par 16 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
Analyste Institution Sharon Shi BOCI Research Ltd. Shaojing Tong BofA Global Research Bo Yu China International Capital Corporation Limited
Afficher 13 plus d'analystes 